AU2010326174A1 - Improved methods and compositions for detecting and treating CEA-expressing cancers - Google Patents

Improved methods and compositions for detecting and treating CEA-expressing cancers Download PDF

Info

Publication number
AU2010326174A1
AU2010326174A1 AU2010326174A AU2010326174A AU2010326174A1 AU 2010326174 A1 AU2010326174 A1 AU 2010326174A1 AU 2010326174 A AU2010326174 A AU 2010326174A AU 2010326174 A AU2010326174 A AU 2010326174A AU 2010326174 A1 AU2010326174 A1 AU 2010326174A1
Authority
AU
Australia
Prior art keywords
cea
protein
sample
antibody
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010326174A
Other languages
English (en)
Inventor
Melissa Damschroder
Scott Hammond
Jiaqi Huang
Michael David Oberst
Li Peng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2010326174A1 publication Critical patent/AU2010326174A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010326174A 2009-12-01 2010-11-29 Improved methods and compositions for detecting and treating CEA-expressing cancers Abandoned AU2010326174A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26558009P 2009-12-01 2009-12-01
US61/265,580 2009-12-01
PCT/US2010/058206 WO2011068758A1 (en) 2009-12-01 2010-11-29 Improved methods and compositions for detecting and treating cea-expressing cancers

Publications (1)

Publication Number Publication Date
AU2010326174A1 true AU2010326174A1 (en) 2012-07-12

Family

ID=44115238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010326174A Abandoned AU2010326174A1 (en) 2009-12-01 2010-11-29 Improved methods and compositions for detecting and treating CEA-expressing cancers

Country Status (6)

Country Link
US (1) US20130035249A1 (https=)
EP (1) EP2507628A4 (https=)
JP (1) JP2013512454A (https=)
AU (1) AU2010326174A1 (https=)
CA (1) CA2782330A1 (https=)
WO (1) WO2011068758A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
JP2014161283A (ja) * 2013-02-26 2014-09-08 Shizuoka Prefecture Ｃｅａｃａｍ５遺伝子のスプライシングバリアント
EP3145531A4 (en) * 2014-05-02 2018-03-21 Icahn School of Medicine at Mount Sinai Ceacam5 peptides for crohn's disease
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
JP2001002700A (ja) * 1999-06-18 2001-01-09 Wako Pure Chem Ind Ltd 癌の判定方法
AU3655301A (en) * 2000-01-25 2001-08-07 Nuvelo, Inc. Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
WO2002040059A2 (en) * 2000-11-01 2002-05-23 American Foundation For Biological Research, Inc. Methods and compositions for inducing cell-mediated immune responses
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
LT1976880T (lt) * 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea

Also Published As

Publication number Publication date
WO2011068758A1 (en) 2011-06-09
CA2782330A1 (en) 2011-06-09
EP2507628A4 (en) 2013-04-24
JP2013512454A (ja) 2013-04-11
US20130035249A1 (en) 2013-02-07
EP2507628A1 (en) 2012-10-10

Similar Documents

Publication Publication Date Title
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
JP6636016B2 (ja) 抗ｂ７−ｈ３抗体及びその診断用途
US9840551B2 (en) Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
US20070207510A1 (en) Methods and compounds for lymphoma cell detection and isolation
US12174195B2 (en) Compositions and methods for assessing the risk of cancer occurrence
US20190310255A1 (en) Proteins
JP2021073437A (ja) 前立腺がんの分析のための組成物及び方法
US20130035249A1 (en) Methods and compositions for detecting and treating cea-expressing cancers
JP2026012693A (ja) 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ
ES2875753T3 (es) Anticuerpo IGF-1R y su utilización para el diagnóstico del cáncer
JP6744885B2 (ja) Ｃｄ３０＋癌の検出と治療
US20240117042A1 (en) Immunohistochemistry methods and kir3dl2-specific reagents
KR101380057B1 (ko) 췌장암의 진단제 및 치료제
WO2019050273A1 (ko) 메티오닐 -티알엔에이 합성효소 및 선방세포 특이적 마커를 이용한 췌장암 진단 방법
EP2776465A1 (en) Monoclonal antibodies against serotransferrin antigens, and uses therefor
JP2018516876A (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
TWI875007B (zh) 靶向epha2之抗體及其在癌症治療中的應用
WO2024081250A1 (en) Small cell lung cancer tumor antigens and uses thereof
HK1243434B (zh) Igf-1r抗体及其诊断癌症的用途
HK1262633B (zh) 用於评估癌症发生的风险的组合物和方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HAMMOND, SCOTT; OBERST, MICHAEL DAVID; PENG, LI; HUANG, JIAQI AND DAMSHRODER, MELISSA

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HAMMOND, SCOTT; OBERST, MICHAEL DAVID; PENG, LI; HUANG, JIAQI AND DAMSCHRODER, MELISSA

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application